Searchable abstracts of presentations at key conferences in endocrinology

ea0037oc8.1 | Endocrine tumours | ECE2015

A role for vault particles as a marker for therapeutic effects against endocrine tumours

Hantel Constanze , Beuschlein Felix

The vault complex, consisting of a major vault protein (MVP), two minor vault proteins (VPARP and TEP1) and small untranslated RNA molecules (vault RNAs 1–4), is considered the largest intracellular ribonucleoprotein particle. Although in recent years, vaults were believed to be involved in multidrug resistance, the exact function of this complex has remained unclear. Recently, we investigated the therapeutic applicability of a Tumour-Vascular-Disrupting Agent (ASA) in pr...

ea0070aep746 | Pituitary and Neuroendocrinology | ECE2020

Preoperative pegvisomant as a potential therapeutic option to improve cardiac function in Acromegaly-induced cardiomyopathy: Two cases

Ernst Matthias E. , Anand Gurpreet , Beuschlein Felix

Introduction: Acromegaly is a rare chronic disorder caused by growth hormone hypersecretion due to GH-producing pituitary adenoma. Surgery is the first-line treatment modality. However, patients with severe cardiac involvement are high-risk candidates for pituitary surgery. These patients may benefit from rapid preoperative biochemical control of acromegaly. There is emerging evidence of efficacy of pegvisomant, a GH-receptor antagonist, (either alone or in combination with so...

ea0073oc14.6 | Oral Communications 14: Across Endocrinology | ECE2021

Endocrine disorders in patients with Fabry Disease: A comprehensive reference center study

Bothou Christina , Beuschlein Felix , Nowak Albina

Fabry Disease (FD) is a rare X–linked metabolic storage disease characterized by a–galactosidase A deficiency and deficient lysosomal function. The patients suffer from diffuse organ manifestations due to the accumulation of the substrate globotriaosylceramide (Gb3), which are only partially reversed by the available enzyme replacement (ERT) therapies. Previous endocrinological studies in patients with FD included small patient numbers or focused on a certain organ...

ea0041gp19 | Adrenal (1) | ECE2016

MUC-1: update on a newly established tumor model for adrenocortical carcinoma

Hantel Constanze , Shapiro Igor , Jung Sara , Reincke Martin , Beuschlein Felix

In an attempt, to overcome the lack of preclinical models for adrenocortical carcinoma (ACC), we recently aimed at the development of patient-individual tumor models for ACC. During these studies one xenograft (MUC-1), derived from a neck metastasis of an ACC, showed extraordinary engraftment properties and sustained tumor growth over several passages in the murine host. During ongoing studies we investigated and compared all currently available xenograft models for ACC (NCI-H...

ea0032p511 | Endocrine tumours and neoplasia | ECE2013

Investigation of novel chemotherapeutic combinations in a tumor model for adrenocortical carcinoma

Jung Sara , Hantel Constanze , Mussack Thomas , Reincke Martin , Beuschlein Felix

Medical treatment of adrenocortical carcinoma (ACC) is limited to common cytotoxic agents, which are usually given in combination with mitotane (M). Recently, we investigated together with M the effects of i) the classical EDP protocol (etoposide, doxorubicin, and cisplatin) and ii) a novel paclitaxel containing scheme PDP (paclitaxel, doxorubicin, and cisplatin) on human NCIh295 cells indicating anti-tumoral superiority of PDP-M over EDP-M regarding cell viability (P...

ea0022p391 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Anti-tumor activity of the tumor-vascular-disrupting agent ASA404 (vadimezan) in endocrine tumor models

Hantel Constanze , Franzev Roman , Ozimek Alexandra , Mussack Thomas , Beuschlein Felix

Vascular disrupting agents (VDAs) differ from angiogenesis inhibitors by attacking established tumor blood vessels rather than preventing growth of new ones. We investigated effects of the tumor-VDA ASA404 against neuroendocrine tumors of the gastroenteropancreatic system (GEP-NETs) and adrenocortical carcinoma (ACC) 24 h after treatment of BON and NCIh295 tumor bearing mice with ASA404 (A), paclitaxel (P) or the combined administration (A+P). A significant decrease in cell pr...

ea0020oc1.5 | Endocrine Tumours | ECE2009

Bone morphogenetic protein 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis

Johnsen Inga , Kappler Roland , Auernhammer Christoph , Beuschlein Felix

Bone morphogenetic proteins (BMPs) have been demonstrated to impact tumorigenesis in a variety of tumors. As for the adrenal cortex, quantitative real time PCR analyses revealed down-regulation of various BMPs (e.g. BMP2, BMP5) in tissue samples from adrenocortical carcinoma and adrenocortical tumor cell lines in comparison to normal adrenal glands. Other members, by contrast, as seen for BMP6 remained unaltered. Integrity of BMP dependent pathways in the investigated cell lin...

ea0020p12 | Adrenal | ECE2009

Short term regulation of aldosterone secretion after stimulation and suppression experiments in mice

Spyroglou Ariadni , Manolopoulou Jenny , Reincke Martin , Bidlingmaier Martin , Beuschlein Felix

Aldosterone is synthesized acutely upon stimulation of the renin-angiotensin-aldosterone system from the cells of the zona glomerulosa. Several enzymes are involved in this steroidogenic process including the steroidogenic acute regulatory protein (StAR), P450 side chain cleavage enzyme (Cyp11a1) and aldosterone synthase, the product of the gene Cyp11b2.We investigated the short time transcriptional regulation of these genes in wild type mi...

ea0016oc4.2 | Bone and adrenal | ECE2008

Reduced fertility rates and high prevalence of testicular adrenal rest tumors (TART) in male patients with congenital adrenal hyperplasia

Reisch Nicole , Flade Linda , Reincke Martin , Beuschlein Felix

Objective: To evaluate reduced fertility rates and their possible causes in a cohort of well controlled male adult patients with congenital adrenal hyperplasia.Methods: We clinically assessed 22 male patients with congenital adrenal hyperplasia (15 salt wasting form, 7 simple virilising, age 18–49) according to their hormonal control. Further, we performed testicular ultrasound, MRI of the testis and a sperm count of each. As laboratory markers 17-O...

ea0016oc4.3 | Bone and adrenal | ECE2008

BMP dependent modulation of adrenocortical growth and function

Johnsen Inga K , Spady Lilia , Shapiro Igor , Beuschlein Felix

Bone morphogenic proteins (BMPs) have been demonstrated to impact tumorigenesis in a variety of tumors. As for the adrenal cortex, BMP6 has been implicated as an important modulator of aldosterone secretion. To screen for alterations of BMP dependent pathways in adrenal tumorigenesis we performed gene profiling experiments. By comparing human adrenal carcinoma (ACC) against normal adrenal glands (Co) we detected a down-regulation of various BMPs (e.g. BMP2, BMP5) which was fur...